Company intelligence / Profile preview
Olpha
Olaine, Latviaolpha.eu ↗
- Ownership
- Private
- Employees
- ~900
- Development stage
- Commercial
01
Overview
Olpha (formerly Olainfarm) is a leading pharmaceutical manufacturer in the Baltic states with over 50 years of experience. The company produces and markets over 60 finished dosage forms, 25 active pharmaceutical ingredients, and more than 20 intermediates. They have successfully registered more than 50 new products and are expanding into Western markets.
- Therapeutic areas
- OncologyEndocrinologyImmunologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small moleculesActive Pharmaceutical Ingredients (APIs)Finished Dosage Forms (FDFs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
NovartisDr. Reddy'sGlenmark GenericsSigma AUAlmirall RankeUQUIFAMIATActavisTevaEgisPHFWorld Health Organization
Beyond the preview
Go deeper on Olpha.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Olpha.